Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 2/20 | 0.60 |
| ▸ | CA9 | Q16790 | 2/20 | 0.60 |
| ▸ | F11 | P03951 | 1/20 | 0.60 |
| ▸ | DAO | P14920 | 3/20 | 0.55 |
| ▸ | CA1 | P00915 | 1/20 | 0.52 |
| ▸ | CA3 | P07451 | 1/20 | 0.52 |
| ▸ | CA4 | P22748 | 1/20 | 0.52 |
| ▸ | CA6 | P23280 | 1/20 | 0.52 |
| ▸ | CA5A | P35218 | 1/20 | 0.52 |
| ▸ | CA7 | P43166 | 1/20 | 0.52 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.52 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.52 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.52 |
| ▸ | AR | P10275 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30874739 | 0.85 | DAO (0.56) | CA12CA9F11DAOCA1 | |
| SCHEMBL708122 | 0.85 | DAO (0.56) | CA12CA9F11DAOCA1 | |
| SCHEMBL4286388 | 0.82 | MGLL (0.48) | CA12CA9F11DAOCA1 | |
| SCHEMBL1081106 | 0.77 | CA12 (0.52) | CA12CA9F11DAOCA1 | |
| SCHEMBL6031111 | 0.77 | CA12 (0.62) | CA12CA9F11CA1CA3 | |
| SCHEMBL786595 | 0.75 | CA12 (0.60) | CA12CA9F11CA1CA3 | |
| SCHEMBL14279696 | 0.75 | CA12 (0.60) | CA12CA9F11CA1CA3 | |
| SCHEMBL1052487 | 0.75 | F11 (1.00) | CA12CA9F11DAOCA1 | |
| SCHEMBL3368797 | 0.75 | CA12 (0.60) | CA12CA9F11CA1CA3 | |
| SCHEMBL1771772 | 0.75 | CA12 (0.60) | CA12CA9F11CA1CA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 285 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11939314-B2 | Quinolin-2-one derivatives | MERCK PATENT GMBH (DE) | 2024-03-26 | — | — | US | claimed |
| US-20230028687-A1 | QUINOLIN-2-ONE DERIVATIVES | MERCK PATENT GMBH (DE) | 2023-01-26 | — | — | US | claimed |
| CN-1172670-C | Liposome composition for improved drug retention | — | 2004-10-27 | — | — | CN | claimed |
| EP-1083881-B1 | LIPOSOME COMPOSITIONs containing a quinolone derivative AND their use as antibacterial agents | ALZA CORP (US) | 2004-08-25 | — | — | EP | claimed |
| EP-0825852-B1 | LIPOSOME DRUG-LOADING METHOD AND COMPOSITION | YISSUM RES DEV CO (IL) | 2004-07-07 | — | — | EP | claimed |
| EP-1176962-B1 | LIPOSOME COMPOSITIONS FOR IMPROVED DRUG RETENTION | ALZA CORP (US) | 2004-02-11 | — | — | EP | claimed |
| CN-1351495-A | Liposome composition for improved drug retention | ALZA CORP (US) | 2002-05-29 | — | — | CN | claimed |
| EP-1176962-A2 | LIPOSOME COMPOSITIONS FOR IMPROVED DRUG RETENTION | Alza Corporation (US) | 2002-02-06 | — | — | EP | claimed |
| EP-1083881-A2 | LIPOSOME COMPOSITION AND METHOD FOR ADMINISTERING A QUINOLONE | ALZA Corporation (US) | 2001-03-21 | — | — | EP | claimed |
| WO-2000066126-A2 | LIPOSOME COMPOSITIONS FOR IMPROVED DRUG RETENTION | ALZA CORPORATION (US) | 2000-11-09 | — | — | WO | claimed |
| US-5434147-A | Bactericides | PROCTOR & GAMBLE PHARMACEUTICALS, INC. (US) | 1995-07-18 | — | — | US | claimed |
| US-5273973-A | Carbapenicillins | NORWICH EATON PHARMACEUTICALS, INC. (US) | 1993-12-28 | — | — | US | claimed |
| EP-0525057-A4 | ANTIMICROBIAL QUINOLONYL LACTAMS | — | 1993-04-07 | — | — | EP | claimed |
| EP-0525057-A1 | ANTIMICROBIAL QUINOLONYL LACTAMS | Norwich Eaton Pharmaceuticals, Inc. (US) | 1993-02-03 | — | — | EP | claimed |
| US-5180719-A | Microbiocides | NORWICH EATON PHARMACEUTICALS, INC. (US) | 1993-01-19 | — | — | US | claimed |
| WO-1991016327-A1 | ANTIMICROBIAL QUINOLONYL LACTAMS | NORWICH EATON PHARMACEUTICALS, INC. (US) | 1991-10-31 | — | — | WO | claimed |
| WO-1990004594-A1 | NOVEL ANTIMICROBIAL QUINOLONYL LACTAM ESTERS | NORWICH EATON PHARMACEUTICALS, INC. (US) | 1990-05-03 | — | — | WO | claimed |
| EP-0366193-A2 | Novel antimicrobial quinolonyl lactams | Norwich Eaton Pharmaceuticals, Inc. (US) | 1990-05-02 | — | — | EP | claimed |
| EP-0366641-A2 | Novel antimicrobial quinolonyl lactam esters | Norwich Eaton Pharmaceuticals, Inc. (US) | 1990-05-02 | — | — | EP | claimed |
| EP-0366189-A2 | Novel antimicrobial lactam-quinolones | Norwich Eaton Pharmaceuticals, Inc. (US) | 1990-05-02 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11939314-B2 | Quinolin-2-one derivatives | KIT, CDK2, CDK1 | CA12 3364/4885CA9 2434/4885F11 263/4885 |
| US-20230028687-A1 | QUINOLIN-2-ONE DERIVATIVES | KIT, CDK2, CDK1 | CA12 3364/4885CA9 2434/4885F11 263/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.